These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 14534913

  • 1. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
    Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J.
    Mov Disord; 2003 Oct; 18(10):1108-14. PubMed ID: 14534913
    [Abstract] [Full Text] [Related]

  • 2. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study.
    Lou JS, Dimitrova DM, Park BS, Johnson SC, Eaton R, Arnold G, Nutt JG.
    Clin Neuropharmacol; 2009 Oct; 32(6):305-10. PubMed ID: 19620846
    [Abstract] [Full Text] [Related]

  • 3. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 4. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG, Shinawi L, Moore S.
    Mov Disord; 2010 Dec 15; 25(16):2724-7. PubMed ID: 20925074
    [Abstract] [Full Text] [Related]

  • 5. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG, Carter JH, Carlson NE.
    Arch Neurol; 2007 Mar 15; 64(3):319-23. PubMed ID: 17353373
    [Abstract] [Full Text] [Related]

  • 6. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G.
    Arch Neurol; 2006 May 15; 63(5):729-35. PubMed ID: 16682542
    [Abstract] [Full Text] [Related]

  • 7. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb 15; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 8. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.
    Clin Neuropharmacol; 2009 Feb 15; 32(4):189-92. PubMed ID: 19620848
    [Abstract] [Full Text] [Related]

  • 9. The dopamine transporter: importance in Parkinson's disease.
    Nutt JG, Carter JH, Sexton GJ.
    Ann Neurol; 2004 Jun 15; 55(6):766-73. PubMed ID: 15174010
    [Abstract] [Full Text] [Related]

  • 10. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul 15; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 11. Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson's disease?
    Elbers R, van Wegen EE, Rochester L, Hetherington V, Nieuwboer A, Willems AM, Jones D, Kwakkel G.
    Mov Disord; 2009 Jul 30; 24(10):1512-8. PubMed ID: 19514069
    [Abstract] [Full Text] [Related]

  • 12. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
    Gunzler SA, Pavel M, Koudelka C, Carlson NE, Nutt JG.
    Clin Neuropharmacol; 2009 Jul 30; 32(2):97-102. PubMed ID: 18978495
    [Abstract] [Full Text] [Related]

  • 13. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H.
    Neurology; 2005 Jan 25; 64(2):216-23. PubMed ID: 15668416
    [Abstract] [Full Text] [Related]

  • 14. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
    Mendonça DA, Menezes K, Jog MS.
    Mov Disord; 2007 Oct 31; 22(14):2070-6. PubMed ID: 17674415
    [Abstract] [Full Text] [Related]

  • 15. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM, Istradefylline 6002-US-013 Study Group.
    Mov Disord; 2008 Nov 15; 23(15):2177-85. PubMed ID: 18831530
    [Abstract] [Full Text] [Related]

  • 16. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr 15; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 17. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 15; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 18. Sensorimotor disinhibition in Parkinson's disease: effects of levodopa.
    Caligiuri MP, Heindel WC, Lohr JB.
    Ann Neurol; 1992 Jan 15; 31(1):53-8. PubMed ID: 1543350
    [Abstract] [Full Text] [Related]

  • 19. CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
    Olanow CW, Werner EG, Gauger LL.
    Clin Neuropharmacol; 1989 Dec 15; 12(6):490-7. PubMed ID: 2575014
    [Abstract] [Full Text] [Related]

  • 20. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I, Parkinson Study Group TEMPO, PRESTO Investigators.
    J Neurol Sci; 2006 Oct 25; 248(1-2):78-83. PubMed ID: 16828804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.